Nasdaq

Medtronic Receives Approval for U.S. Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation

Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of ...
Nasdaq

Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling

Medtronic plc MDT announced a major regulatory advancement in the fast-growing neuromodulation space. Per the announcement, the company received revised commercial labeling approval from the FDA for ...
BioWorld

Study shows sustained back pain relief with DTM SCS therapy using Intellis

Medtronic plc reported 12-month data from a large, multicenter, randomized controlled clinical trial affirming the superiority of differential target multiplexed spinal cord stimulation (DTM SCS) in ...